Drugs / MPSV4
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT01732627 Comparator | Nov 2012 → Jan 2013 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT06700148 Comparator | Dec 2024 → Aug 2025 overdue | meningococcal meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06226714 Comparator | Mar → Sep 2024 overdue | meningococcal meningitis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02842866 Comparator | Jul 2016 → Feb 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MPSV4 | “MenACYW-TT compared with a quadrivalent meningococcal polysaccharide vaccine (MPSV4) in 301 healthy adults aged ≥56 y in the US (NCT01732627).” PMID 32233961 ↗ Apr 20203“MPSV4 vaccine (n = 455) was administered on Day 0” PMID 32387012 ↗ May 2020 |
| Known as | ACYW135 Group Meningococcal Polysaccharide Vaccine | “ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4)” NCT06226714 ↗ |
| Modality | Vaccine | “MenACYW-TT compared with a quadrivalent meningococcal polysaccharide vaccine (MPSV4) in 301 healthy adults aged ≥56 y in the US (NCT01732627).” PMID 32233961 ↗ Apr 2020 |
| Route | Subcutaneous | “Subcutaneous (SC)” NCT02842866 ↗ |